

Application No. 10/717,378

Reply to Office Action

*AMENDMENTS TO THE SPECIFICATION*

At page 7, line 9, please insert the following paragraph:

Another advantage of the present invention is that approximately 3-fold less irinotecan accumulates in cardiac tissue as compared to conventional irinotecan. In addition, the area under the irinotecan plasma concentration curve is 200-fold higher than with the conventional irinotecan formulation. The plasma half-life of the inventive composition is approximately 10-fold greater than with the conventional irinotecan formulation.